Notice of Australian Patent Registration for Redasemutide-Related Use in Fatty Liver and Non-Alcoholic Steatohepatitis

Key Points

This announcement concerns the registration of a use patent in Australia for treatment of fatty liver and non-alcoholic steatohepatitis (NASH). The patent relates to therapeutic use of the regenerative induction pharmaceutical candidate Redasemutide (development code: S-005151), with applicants StemRIM, Osaka University, and Niigata University. At present, there is no impact on full-year results for the fiscal year ending July 2027, and patent grant secures the possibility of development in Australia. Uncertainties include that the registration number is not yet determined.

Impact on Investors and Future Outlook

While the potential for new therapeutic areas accompanying indication expansion is acknowledged, the current disclosure does not specify financial effects. In the long term, indication expansion for Redasemutide could enhance the value of the company's R&D portfolio, but this information does not directly affect recent earnings. If disclosure items arise following notice of patent grant, they will be published promptly.